Is my portfolio
One Report to Answer all your Questions!
Dr. Reddys Laboratories Ltd.
BSE: 500124 | NSE: DRREDDY
Large Cap | Pharmaceuticals & Drugs
1166.45
-9.10 (-0.77%) Dr Reddys gets US FDA nod for Azacitidine Injection
Date: 17-09-2013Pharma major Dr Reddys Laboratories has received US Food and Drug Administration (FDA) approval for Azacitidine Injection 100 mg/vial, a bioequivalent generic version of VIDAZA (azacitidine for injection) on September 16, 2013. The launch of product in the market is planned in the near-term.
The VIDAZA brand had U.S. sales of approximately $378.5 Million for the most recent twelve months ending July 2013 according to IMS Health.
Dr Reddy's Azacitidine for Injection 100 mg/vial is available in single use-vials.